Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Therapie ; 76(3): 215-219, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-32951867

RESUMEN

Patients with auto-immune disease are more susceptible to infection than similar populations without auto-immune disease. Vaccination seems to be one of the most effective methods to prevent patients from possible infections, but may be impaired by concomitant immunomodulators. The aim of this review was to evaluate the effect of immunosuppressive drugs on vaccination efficiency. We found that the majority of studies confirms that neither the use of corticosteroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) nor the use of biological agents, except rituximab, reduce the efficacy of inactivated vaccines such as pneumococcal and influenza vaccines. Even if rituximab has been shown to reduce humoral responses following influenza and pneumococcal vaccination, this response can be modestly restored 6-10 months after rituximab administration. To sum up, treatment guidelines recommending routine use of pneumococcal and influenza vaccines for immune compromised patients should be followed in order to avoid severe infections.


Asunto(s)
Antirreumáticos , Vacunas contra la Influenza , Enfermedades Reumáticas , Antirreumáticos/uso terapéutico , Humanos , Inmunosupresores/uso terapéutico , Vacunas contra la Influenza/uso terapéutico , Enfermedades Reumáticas/tratamiento farmacológico , Vacunación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA